Zenagamtide
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semagl
Novo Nordisk · Phase 1 · Recruiting · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide and Zenagamtide | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide and Zenagamtide: endpoint not reported